RecruitingPhase 1NCT06578676

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

A Clinical Study to Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults


Sponsor

Hyundai Pharm

Enrollment

56 participants

Start Date

Jun 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether there is any interaction between two experimental drugs — HODO-22251 and HODO-22252 — when taken together in healthy adults, to make sure it is safe to combine them in future studies. **You may be eligible if...** - You are 19 years or older - You are a healthy adult volunteer with no significant medical conditions - Your body mass index (BMI) is between 18.5 and 29.9 (normal to slightly overweight range) **You may NOT be eligible if...** - You have any untreated or ongoing medical conditions that could affect how the body processes medications - You have relevant abnormal findings in blood tests, blood pressure, or heart rhythm - You are pregnant or breastfeeding - You have a known allergy to the study drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEmpagliflozin 25 MG

PO, QD

DRUGEzetimibe/Rosuvastatin 10/10mg

PO, QD

DRUGEmpagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg

PO, QD


Locations(1)

Kyungpook national university hospital

Daegu, Gyeongsangbuk-do, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06578676


Related Trials